A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy

• Published in: Asia Pacific allergy 2014-07, Vol.4 (3), p.156-163
• Main Authors: Thong, Bernard Yu-Hor, Chia, Faith Li-Ann, Tan, Sze-Chin, Tan, Teck-Choon, Leong, Khai-Pang, Tan, Justina Wei-Lyn, Tang, Chwee-Ying, Hou, Jin-Feng, Chan, Grace Yin-Lai, Chng, Hiok-Hee
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2233-8276; 2233-8268
• DOI: 10.5415/apallergy.2014.4.3.156

Antituberculosis (anti-TB) drug allergy often involves multiple concurrently administered drugs which subsequently need to be reinitiated as no better alternatives exist. To describe the results of tailored sequential desensitization-rechallenge (D-R) for anti-TB drug allergy. Consecutive patients who had undergone D-R to anti-TB drugs between 1 September 1997 and 31 January 2012 were recruited. Following resolution of the acute reaction, anti-TB drug was restarted at 1:6,000 to 1:3 of the final daily dose (FDD), with gradual single or multiple step daily dose escalation to the FDD. Subsequent drugs were sequentially added ≥3 days later when the preceding drug was tolerated. Full blood count and liver function tests were monitored prior to addition of each new drug. There were 11 patients of whom 10 were male, predominantly Chinese (8 patients). Regimens comprised at least 3 drugs: isoniazid (INH), rifampicin (RIF), ethambutol (EMB), pyrazinamide (PZA), or streptomycin. All patients had nonimmediate reactions, with cutaneous eruptions, where maculopapular exanthema (MPE) was the most common (8 patients). Drug-induced hypersensitivity syndrome (DIHS) occurred in 6 patients, and Stevens Johnson syndrome (SJS) in 2 patients. D-R to INH was successful in 7/9 patients (77.8%) and to RIF/EMB/PZA/streptomycin in all. Of the 2 patients who failed INH D-R, 1 developed fever and MPE on day 3, the other MPE on day 8. D-R with INH and RIF respectively was successful in 2 patients with SJS. Among DIHS patients, 1 failed D-R with INH (fever and MPE on day 3). There were 23/25 (92%) successful D-R among the 11 patients. All patients completed TB treatment of ≥5 months' duration with no cases of drug-resistant TB. Tailored sequential TB drug D-R is successful where no better alternative therapies are available, with careful dose escalation and close monitoring, and after a careful risk-benefit assessment.